Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding
specificity to CD20. It was the first therapeutic antibody approved for oncology patients and …

Diffuse large B cell lymphoma (DLBCL) is a highly heterogeneous lymphoid neoplasm with
variations in gene expression profiles and genetic alterations, which lead to substantial …

The incidence of lymphoma has gradually increased over previous decades, and it ranks
among the ten most prevalent cancers worldwide. With the development of targeted …

Genetic classification helps to disclose molecular heterogeneity and therapeutic implications
in diffuse large B-cell lymphoma (DLBCL). Using whole exome/genome sequencing, RNA …

TP53 gene alteration confers inferior prognosis in refractory/relapse aggressive B-cell non-
Hodgkin lymphoma (r/r B-NHL). From September 2016 to September 2020, 257 r/r B-NHL …

Diffuse large B-cell lymphoma (DLBCL) patients are typically treated with
immunochemotherapy containing rituximab (rituximab, cyclophosphamide …

Glofitamab, a novel CD20xCD3, T-cell–engaging bispecific antibody, exhibited single-agent
activity in Study NP30179, a first-in-human, phase 1 trial in relapsed/refractory B-cell non …

Background Mutations of the tumour-suppressor gene TP53 are the most frequent somatic
genomic alterations in head and neck squamous cell carcinoma (HNSCC). However, it is not …

Children with B-cell non-Hodgkin lymphoma (B-NHL) have an excellent chance of survival,
however, current clinical risk stratification places as many as half of patients in a high-risk …

Survival for patients diagnosed with mantle cell lymphoma (MCL) has improved drastically in
recent years. However, patients carrying mutations in tumour protein p53 (TP53) do not …